2023 SCHEDULE

The registration desk will be open Wednesday, April 12 from 5:30-6:30 PM. Staff will be on hand to hand out badges and answer any questions.

THURSDAY, APRIL 13 - PHARMACOLOGY PRECONFERENCE AND GENERAL SESSIONS
7:30 AMBreakfast
8:00 AMProduct Theater from Pfizer, Inc: Transthyretin Amyloid Cardiomyopathy: Recognition, Diagnosis, and Treatment
8:45 AMWelcome to Pharmacology Preconference
9:00 AMCardiometabolic Treatments for Obesity
Angela Golden DNP, FNP-C, FAANP, FOMA
9:50 AMActivity Break
10:00 AMTherapies to Treat Inflammation in Cardiovascular Disease
Joseph Saseen, PharmD, FNLA, CLS
10:50 AMUpdate on Stroke: Tenecteplase (TNK)
Shavonne Williams, MN, APRN, ACNS-BC, ANVP-BC, SCRN, CCRN-K
11:40 PMStretch Break
12:00 PMLunch Served
Product Theater from Kiniksa Pharmaceuticals:
The Burden of Recurrent Pericarditis
12:45 PMAntiplatelet Therapy in Primary Prevention
Erin Michos MD, MHS, FACC, FAHA, FASE, FASPC
1:35 PMAnnouncements
1:40 PMExhibit Hall Open and Beverage Break
3:00 PMWelcome to General Sessions
3:15 PMOpening Keynote - Evaluating Chest Pain: Cardiac vs. Non-Cardiac
Debabrata Mukherjee MD, FACC, FAHA, FSCAI
4:15 PMHeart Failure Prevention and Treatment: Latest Guidelines
Nancy Albert, PhD, CCNS, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN
5:00 PMAnnouncements
5:15 PMEntertainment - Stooges Brass Band
5:30 PMOpening Reception in the Exhibit Hall with Poster Presentations
7:00 PMDinner Served
Product Theater from Bristol-Myers Squibb:
A Case-based Discussion on the Unique Role of Cardiac Myosin Inhibition for Adult Patients with NYHA Class II-III Obstructive HCM
FRIDAY, APRIL 14 - GENERAL SESSIONS
7:30 AMBreakfast Served
8:00 AMProduct Theater from Novartis Pharmaceuticals:
Rethinking the Approach:
Management of Elevated LDL-C in patients with ASCVD
8:15 AMWelcome
Poster Winners Announced
9:00 AMThe Role of LP(a) in CVD Risk
Keith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA
9:45 AMKidney Health Equity
Flor Alvarado, MD, MPH
10:30 AMActivity Break - Chapter Award Announced
10:40 AMBehavioral Interventions: Impact on Cardiovascular Risk Factors
Valerie Hoover, PhD
11:25 AMStructural Heart Interventions: What’s New?
Kimberly Guibone, NP, ACNP-BC, FACC
12:10 PMOral Abstract Presentations
12:45 PMBeverage Break and Lunch Served
1:00 PMDisease State Theater from Janssen Pharmaceuticals, Inc:
Call to Action in Peripheral Artery Disease
1:45 PMExhibit Hall
3:00 PMBreak Out Sessions (pick one)
Cardiac Rehab: What’s in it for You and Your Patients?
Robert Scales, PhD
CVD Diagnostics: Demystifying which, when, and why?
Abhinav Saxena, MD
Rare Arrythmias: Do you know what to look for?
Dan Sorajja MD, FACC, FHRS
4:00 PM - 4:50 PMBreak Out Sessions (pick one)
Cardiac Rehab: What’s in it for You and Your Patients?
Robert Scales, PhD
CVD Diagnostics: Demystifying which, when, and why?
Abhinav Saxena, MD
Rare Arrythmias: Do you know what to look for?
Dan Sorajja MD, FACC, FHRS
SATURDAY, APRIL 15 - GENERAL SESSIONS
7:30 AMBreakfast
8:00 AMWelcome
8:05 AMProduct Theater from Regeneron Pharmaceuticals, Inc.:
Discover EVKEEZA® (EVINACUMAB-DGNB)
8:50 AMAward and Presidential Transition
9:10 AMMobilizing Nurses to Reduce Hypertension Burden
Janet Wright, MD, FACC
9:55 AMActivity Break
10:05 AMHypertrophic Cardiomyopathy: Comparing Traditional & Novel Treatments
Heidi Salisbury RN, MSN, CNS-BC, ACGN
10:50 AMReflecting on Well-Being: Focus on the Health of Nurses
Keith Jones, MA, BS
11:50 AMClosing and Prize Drawing
12:00 PMMeeting Adjourns

For more information on each program topic, see the Learning Objectives.

ACCREDITATION STATEMENT

This educational activity is provided by the Preventive Cardiovascular Nurses Association (PCNA). Multiple educational grants have been requested to support this program. PCNA is approved as a provider of nurse practitioner continuing education (CE) programs by the American Association of Nurse Practitioners (AANP), provider number 030602. This program was planned in accordance with AANP CE Policies and Commercial Support Standards.